Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
about
Optimal management of seizures associated with tuberous sclerosis complex: current and emerging optionsUpdates of mTOR inhibitorsMesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomasRibosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to FunctionRoles of mTOR Signaling in Brain DevelopmentEpilepsy related to developmental tumors and malformations of cortical developmentThe molecular biology of WHO grade I astrocytomasPotential for treatment of severe autism in tuberous sclerosis complexPathological and molecular advances in pediatric low-grade astrocytomaGiant cells: contradiction to two-hit model of tuber formation?Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decreaseThe differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficitsTopical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsIdentification of the miRNA-target gene regulatory network in intracranial aneurysm based on microarray expression data.The genomic landscape of tuberous sclerosis complexEvidence for population variation in TSC1 and TSC2 gene expressionBiallelic TSC gene inactivation in tuberous sclerosis complexLymphangioleiomyomatosis and TSC2-/- cellsThe complexes of mammalian target of rapamycin.Oral findings in 58 adults with tuberous sclerosis complexAnalysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events.Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.The mTOR signaling pathway as a treatment target for intracranial neoplasmsMonoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.Postnatal neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration following single-cell Tsc1 deletion.Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictionsLhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphansFetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammationEverolimus long-term safety and efficacy in subependymal giant cell astrocytoma.Akt-dependent and -independent mechanisms of mTOR regulation in cancerLoss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.The pathogenesis and imaging of the tuberous sclerosis complex.The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells
P2860
Q22305852-FF52FE2E-5D98-4AB3-BE0D-11F74F2F14CBQ24607170-03BEF328-36B1-49F0-96D6-0F7E0BEE9FF6Q24656058-D18EBBBE-F3FE-46C6-ABC9-5741AF6A1FAEQ26770762-112C19C4-7CC2-4D2F-A907-44260A245F99Q26786097-335B24A7-D8AF-4D00-8892-19E0B73F41F0Q26829946-B22D20E4-CA97-41DE-B106-DBB96FA301BEQ27010414-0A81450C-02B6-4E6A-99A3-F32AFAA52732Q27021739-4224616D-C03D-4DD1-80F3-47F49E388090Q27026123-4935D9DA-40EC-4822-A14F-1E8D51E44436Q28256696-44D26490-1D05-46B4-9B76-121C2209F147Q28476810-641D9478-6386-4EDE-9FFC-1CFCA0B1150DQ30518266-6D4DA0D3-DD82-441B-93C4-3734E1A2088AQ30597707-19C9CF3C-B246-4183-A270-5F2D9612F928Q33316872-1AB4C240-E67E-46D6-9333-B6BDB6B4B387Q33711691-64B43901-0999-4E65-9D90-4C1842174811Q33744043-88480C16-C64E-424D-BC59-F41E49AF2DFEQ33826893-9F6B3E45-0891-4839-A083-9C6AA213DF43Q33827600-5BA794B7-3701-4895-8B56-97FA5F5E1FB1Q33899858-44BB2121-661E-48D1-99C9-2DDA49C7AC56Q33904951-5CA43B23-B0F5-4E39-B719-AF62C8A70806Q34116818-C0FB8D47-0857-466B-8583-C4B373B86CB5Q34162958-33A094AF-8054-4306-A749-ACCEF9EE7AAAQ34182980-8AB69BCD-8303-4E08-BF65-7466CAFF3937Q34467227-78C57186-4A0F-4B52-8EBA-1B00683C69E1Q34562010-F3E1B941-F4CD-4CE2-AD5D-C0A0DBE11272Q34589342-6FC0E097-2E56-487B-94D4-5ED73392CD5EQ34755802-CD89FEBD-67F6-469F-851C-11788D908EC2Q34886859-F77202F4-8EC1-4DE7-81AF-E79ACDAC1FB7Q35122010-C7448FB2-A8AD-4592-961E-555F45494DFAQ35278772-EE6BD950-502C-4E8B-B477-9150FB9F9365Q35688636-3EF67631-12E3-4F82-B3B7-D6705A72FAF9Q35881144-EB771057-E0AA-44A6-9F3A-2BE8608578E2Q36100341-3289FBF6-7EB9-4885-A5DB-E7AF2CA5E0F8Q36330644-07C8D6FF-B480-4883-8FCC-9DA325B1EBC9Q36457269-895138BC-F530-40A6-8B26-40B592DDA7C3Q36659706-D9C24410-DB32-4166-BCE7-7C274DF85104Q37114404-64333743-3638-4CEB-B66A-F79DA09525E2Q37128350-201E6946-1786-48DE-A496-AFB5D12526CBQ37139373-83C1DF34-1062-4EBA-A596-A9DC7307DC49Q37197352-8B754634-BC70-43AB-B878-CF25605FBDD2
P2860
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@en
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@nl
type
label
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@en
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@nl
prefLabel
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@en
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.
@nl
P2093
P2860
P356
P1476
Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation
@en
P2093
David J Kwiatkowski
Grajkowska Wieslawa
Hongbing Zhang
Jennifer A Chan
Joanna Lewin-Kowalik
Penelope S Roberts
P2860
P304
P356
10.1093/JNEN/63.12.1236
P577
2004-12-01T00:00:00Z